摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

benzyl (3S)-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate | 195832-14-5

中文名称
——
中文别名
——
英文名称
benzyl (3S)-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate
英文别名
S-3-hydroxymethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester;(S)-N-benzyloxycarbonyl-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline
benzyl (3S)-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate化学式
CAS
195832-14-5
化学式
C18H19NO3
mdl
——
分子量
297.354
InChiKey
QDSSMMQSDYDNRV-KRWDZBQOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    476.8±45.0 °C(Predicted)
  • 密度:
    1.217±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    申请人:LES LABORATOIRES SERVIER
    公开号:US20150031673A1
    公开(公告)日:2015-01-29
    Compounds of formula (I): wherein A 1 , A 2 , R a , R b , R c , R d , R 3 , R 4 , R 5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
    式(I)的化合物: 其中A 1 ,A 2 ,R a ,R b ,R c ,R d ,R 3 ,R 4 ,R 5 和T的定义如描述中所述。 含有这些化合物的药物产品对于治疗涉及凋亡缺陷的病理,如癌症、自身免疫疾病和免疫系统疾病,具有益处。
  • [EN] NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSÉS ISOINDOLINE OU ISOQUINOLÉINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    申请人:SERVIER LAB
    公开号:WO2015011164A1
    公开(公告)日:2015-01-29
    Compounds of formula (I): (I) wherein Het, R3, R4, R5, R7, R8, R9, T, p, p', q, and q' are as defined in the description are pro-apoptotic agents useful in the treatment of cancers and of auto-immune and immune system diseases.
    式(I)的化合物:其中Het、R3、R4、R5、R7、R8、R9、T、p、p'、q和q'的定义如描述中所定义,是在治疗癌症以及自身免疫和免疫系统疾病中有用的促凋亡剂。
  • Tetrahydroisoquinolinealkanol derivatives and pharmaceutical
    申请人:SK Corporation
    公开号:US05955471A1
    公开(公告)日:1999-09-21
    The present invention provides novel 1,2,3,4-tetrahydroisoquinoline carbamate and thiocarbamate derivatives represented by Formula I ##STR1## wherein: X.sub.1 and X.sub.2 are the same or different from each other and independently represent a a member selected from the group consisting of hydrogen, alkyl, alkoxy, thioalkoxy, halogen, hydroxy, nitro and trifluorocarbon; Y is a member selected from the group consisting of oxygen and sulfur; R.sub.1 is a member selected from the group consisting of hydrogen, alkyl, arylalkyl, and CONHR' where R' is selected from the group consisting of hydrogen, alkyl, arylalkyl and aryl; R.sub.2 and R.sub.3 are the same or different from each other and independently represent a member selected from the group consisting of hydrogen, alkyl, arylalkyl, and cycloalkyl, or R.sub.2 and R.sub.3 may form a 5 to 7-membered ring together with the nitrogen atom to which they are bonded; R.sub.4 is a member selected from the group consisting of hydrogen or lower alkyl; and nontoxic pharmacologically acceptable salts thereof. Compounds are useful in the treatment of central nervous system disorders, including depression.
    本发明提供了新颖的1,2,3,4-四氢异喹啉氨基甲酸酯和硫代氨基甲酸酯衍生物,其结构如式I所示 ##STR1## 其中:X1和X2彼此相同或不同,独立地表示氢、烷基、烷氧基、硫代烷氧基、卤素、羟基、硝基和三氟甲基中的一种;Y表示氧或硫;R1表示氢、烷基、芳基烷基和CONHR'中的一种,其中R'表示氢、烷基、芳基烷基和芳基中的一种;R2和R3彼此相同或不同,独立地表示氢、烷基、芳基烷基和环烷基中的一种,或者R2和R3可以与它们所连接的氮原子一起形成5至7元环;R4表示氢或低级烷基;以及其无毒的药理学上可接受的盐。这些化合物可用于治疗中枢神经系统疾病,包括抑郁症。
  • 吲哚和吡咯衍生物、它们的制备方法和含有它 们的药物组合物
    申请人:法国施维雅药厂
    公开号:CN105408321B
    公开(公告)日:2019-03-08
    本发明涉及式(I)化合物,其中Ra、Rb、Rc、Rd、R3、R4、R5、A1、A2、T和W如说明书中定义。本发明还涉及含有其的药物。
  • INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    申请人:LES LABORATOIRES SERVIER
    公开号:US20160152599A1
    公开(公告)日:2016-06-02
    Compounds of formula (I): wherein R a , R b , R c , R d , R 3 , R 4 , R 5 , A 1 , A 2 , T and W are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
    式(I)的化合物:其中Ra、Rb、Rc、Rd、R3、R4、R5、A1、A2、T和W的定义如描述中所述。含有这些化合物的药品对治疗涉及凋亡缺陷的病理病变,如癌症、自身免疫疾病和免疫系统疾病等,具有益处。
查看更多